Hematological oncologyAdolescentAdultAgedFemaleHumans
Five-Year Follow-Up of Patients With Relapsed and Refractory Classic Hodgkin Lymphoma Treated With Low-Dose Nivolumab (40 mg): A Matched Cohort Study With Standard-Dose Therapy.
Liudmila Fedorova, Kirill Lepik, Polina Kotselyabina, Aminat Balaeva, Andrey Chekalov, Elena Kondakova, Ivan Moiseev, Natalia Mikhailova, Alexander Kulagin
Published: 202510.1002/hon.70146
Abstract
The use of low-dose PD-1 inhibitors may offer a promising treatment strategy for patients with refractory Hodgkin lymphoma. This approach has the potential to mitigate the financial toxicity commonly associated with immune checkpoint inhibitors while…
Preview only. Read the full abstract at the source